LifeMine Therapeutics’ Post

Elevate Your Research with Expert Medical Monitoring Services 🚀🔬 Are you struggling to find experienced physicians to oversee the safety of your trials? Look no further! At My Medical Department, our in-house #physicians can expertly manage your #medicalmonitoring needs. What Sets My Medical Department Apart from Other Solutions? ✨ Expertise: Our team of physicians have extensive clinical trial experience, covering all phases of clinical trials and various therapeutic areas – from oncology, metabolic, immunology, rare diseases, and more. You can trust our team to oversee and protect the safety of your subjects and patients. 🌍 Coverage: With physicians located across Australia, Latin America, and the United Kingdom, My Medical Department offers comprehensive 24/7 medical oversight for your trials. 🤝 Comprehensive Support: We understand that every trial is unique. Our team provides comprehensive assistance at every stage of the process, from protocol development and medical monitoring plans to hotlines for site and study support, safety review committees, safety data analysis, and continuous safety oversight. 🏆 Proven Track Record: We have a history of successful collaborations with research teams globally. Our rapid and smooth implementation ensures timely support and compliance with regulatory standards, enhancing safety oversight and enabling you to make informed decisions about your trial. Are you ready to elevate your clinical trials to new heights? Don't let the challenge of finding experienced physicians hold you back. Reach out to our team to learn more about how our medical monitoring services can support your research endeavours. #Pharmaceutical #ClinicalTrials #MedicalResearch #HealthcareInnovation #PatientSafety #MedicalMonitoring #ClinicalDevelopment

Start your program the right way. Our experts in #earlyclinicaldevelopment and #clinicalpharmacology set you up for #drugdevelopment efficiency with highly coordinated efforts to anticipate potential challenges, recruit the right patients, engage top investigators and design a trial that will build a platform for later-stage success.

Navigating the intersection of clinical development and medical affairs is more crucial now than ever before. As we dive deeper into the lifecycle of drug development, the synergy between these two spheres emerges as a decisive factor for success. Starting from Phase 1, integrating medical affairs advice isn't just beneficial—it's imperative. The early involvement of these professionals ensures that clinical trials are meticulously crafted with a clear vision of the end goal. It's about asking the right questions early on: Are we targeting the appropriate patient population? Are trial designs optimized for efficacy and safety? How do our strategies align with patient needs and market expectations? It's a collaborative push toward a successful drug launch. With medical affairs' strategic insights, clinical teams can make informed decisions that resonate with both the scientific community and market demands. This foresight can pave the way to seamless Phase 2 and 3 transitions, where patient numbers, trial designs, and combinational approaches come under the spotlight. If you have a background in Medical Affairs and Clinical Development for solid tumor oncology, please get in touch. I have a Senior Director position available which pools together Medical Affairs Pipeline and Clinical Development Strategy. #ClinicalDevelopment #MedicalAffairs #DrugDevelopment

"As we navigate through the ever-evolving landscape of healthcare, clinical trials stand at the forefront of the innovations leading us into the future. But can Clinical Trial Management truly revolutionize future healthcare solutions? Our latest article delves into this pivotal question. We have the honor of featuring the amazing start-up Fortrea and its founder (please include the name). Rooted in Durham, North Carolina, Fortrea is driving healthcare innovation worldwide. They are committed to providing comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. Peek into the future of healthcare today. Join the conversation and discover how Clinical Trial Management may indeed be the paradigm shift in our healthcare industry. https://lnkd.in/ewGr5-YF #Healthcare #Innovation #ClinicalTrials #StartUp #HealthTech"

In an op-ed published in BioCentury Inc. May 14, Gigi Hirsch of NEWDIGS Initiative at Tufts Medical Center and Jane F. Barlow, MD, MPH, MBA of Real Endpoints make the case that the only way to have our cake (medical innovation) and to be able to eat it (afford the innovation) is to increase health efficiency – that is, capturing the full value of medical products. And that means consistently doing the following: using the innovations where they’re needed; not using them where they’re not needed; innovating in the use of cheaper medicines and investing in systems changes to support their use. Reducing drug costs alone, with blunt instruments like the IRA, isn’t going to create the investment incentives that result in therapies that will make people healthier. Similarly, pursuing innovative science without also investing in innovations in health efficiency creates a vicious circle where cost containment becomes the primary rallying cry. Hirsch and Barlow suggest, as a start, three ways to begin to break this vicious circle: 1. Recommit to precision medicine (in particular, make diagnostic-driven drug therapy routine medical practice); 2. Build infrastructure to scale value-based payments; 3. Where applicable, repurpose generic drugs to save lives and lower costs. By catalyzing multi-stakeholder collaborations, drug companies have an opportunity to play a leading role accelerating healthcare efficiency in these three areas. As the authors rightly point out, drug companies also have much to gain by helping the overall system catch up with science. After all, what’s the point of a breakthrough that doesn’t reach ALL the patients who need it? #healthcare #value #innovation #efficiency #drugpricing #newmodels #healthcaredelivery #affordability #BioCentury #editorial cc Roger Longman Jeff Berkowitz Michael Sherman Brian Reid Gigi Hirsch Jane F. Barlow, MD, MPH, MBA Mark Trusheim https://lnkd.in/g2naerXA  

Clinical trials are vital as the basis of developing safe and effective drugs, but they can be slow and expensive. The patient burden can also be high. The travel time, combined with the time spent at the clinic for visits, can result in absences from work or school, or issues with caring responsibilities. There are barriers that impact the access to a study for older people, neurodiverse people, people from the LGBTQIA+ community and people from ethnically minoritised groups. All of these can have an impact on recruitment and retention. One of the solutions to this could be the virtual clinical tria. These have potential to make the drug development process more efficient, more inclusive and more patient-centric, as well as widening the geographic area from which patients can be selected. https://lnkd.in/gg5bAtzM

🌟 Discover the Future of Medical Research with Adaptive Clinical Trials! 🌟 Would you be shocked to hear that the long-rooted traditional trials may not be the best option? It's time to rethink our approach to clinical research. 🔍 Traditional Clinical Trials: We all know about the long-established methods with rigid protocols and fixed designs. While these have laid the foundation for medical advancements, they come with limitations. 🚀 Adaptive Clinical Trials: Imagine a more flexible approach where trials can adapt in real-time based on interim results. This means enhanced patient safety, faster drug development, and more efficient use of resources. I'm excited to share an insightful blog that dives deep into the world of adaptive clinical trials and how they are transforming the landscape of clinical research. Dive into the full article here: https://lnkd.in/dMUcEv_7 Let's embrace the future of clinical research together! 🌐 #ClinicalTrials #MedicalInnovation #AdaptiveDesign #HealthcareRevolution #Pharma #Biotech

Have you considered how the diversity of clinical trial participants can impact the outcomes and approval of new drugs in the BioPharma industry? 🤔 Diversity, Equity, and Inclusion (DEI) are crucial to get a complete picture of a drug’s safety and efficacy across different populations. Despite its importance, the clinical trial participant population often doesn't reflect individuals in the real world. Recognizing this issue, the FDA is producing guidance documents to ensure that clinical studies appropriately test the product in a representative sample of the intended use population (read more here: https://lnkd.in/epvUTzX3). 🌎 However, there are barriers that hinder participation of specific groups in clinical trials, making it challenging to have a representative sample of the intended use population. Some of these barriers involve geographic and socioeconomic factors, access to information and language barriers and having a restrictive study design. ✔️ By focusing on recruiting patients from the diverse ethnicities that reflect the drug’s intended use population, partnering with community hospitals, and enhancing diversity among trial participants and researchers, the BioPharma industry can ensure more comprehensive and reliable research outcomes, aligning with FDA guidelines and avoiding costly delays and compliance issues.   ➡️ At myTomorrows, we strive to support BioPharma to make clinical trials more accessible and inclusive. By acting as a connected hub between patients, advocacy groups, physicians, and BioPharma, we aim to directly address some of these barriers. Curious to know more about DEI in clinical trial recruitment? Read our blog: https://lnkd.in/eSTQT2ZC Together, we can ensure a brighter, more inclusive future for medical research. #ClinicalTrials #DEI #DiversityEquityInclusion #HealthEquity #MedicalResearch #InclusiveResearch

🌟 Pioneering Diversity in Clinical Trials! 🌟 Amgen and Merck have taken a groundbreaking step by becoming the first industry partners in the Equitable Breakthroughs in Medicine Development (EQBMED) initiative. This collaboration is set to transform clinical trial diversity! Here are three key takeaways: 1️⃣ Boosting Diversity: This partnership aims to enhance diversity in clinical trials, ensuring that underrepresented populations are included and their unique health needs are addressed. 🌍 2️⃣ Community Engagement: By working closely with local trial sites and communities, Amgen and Merck will foster stronger relationships and trust, making clinical trials more accessible and effective. 🤝 3️⃣ Infrastructure Enhancement: Amgen will enhance infrastructure and trial capabilities at community-facing sites, while Merck will develop a clinical trial site assessment model and provide patient support services. 🏥 At Radyus Research, we are committed to supporting founders in navigating the complex journey of getting their therapeutics into clinical trials. Our team works closely with innovators to design robust studies, secure funding, and ensure regulatory compliance, ultimately accelerating the path to market. 🚀 This initiative is a significant leap forward for biotech, paving the way for more inclusive and comprehensive medical research. Kudos to Amgen, Merck, and EQBMED for leading the charge! 👏 #ClinicalTrials #DiversityInResearch #Biotech #HealthcareInnovation #Amgen #Merck #EQBMED #MedicalResearch #CommunityHealth #RadyusResearch https://lnkd.in/e4e4xJN5

Today's #ClinicalTrialsDay! Join us in celebrating how far research has come, the healthcare professionals making the difference & the impact they have on improving patients’ lives worldwide. In this blog, Oren Cohen, MD, Chief Medical Officer and President of Clinical Pharmacology shares his reflections on this important day! https://lnkd.in/emzbmKuY